Gowling WLG advises Aegerion Pharmaceuticals on licensing agreement

2 minute read
20 December 2016

Gowling WLG's Life Sciences team  has acted for client Aegerion Pharmaceuticals Inc., a subsidiary of Novelion Therapeutics, Inc. in relation to an agreement with Amryt Pharma under which  Amryt is granted the exclusive rights to LOJUXTA® (lomitapide®) hard capsules in certain European and Middle Eastern territories. 

LOJUXTA® is currently approved by the European Commission and the agreement will allow Amryt to exclusively promote and distribute the medicine in the European Economic Area, Switzerland, Turkey and certain Middle Eastern and North African countries. The deal, was led by partner Patrick Duxbury. Gowling WLG worked closely with Vice President, EMEA Legal at Aegerion, Janet Kidd. The firm advised Aegerion on the drafting and negotiation of the transaction documents.

Patrick Duxbury commented: "We are delighted that this transaction between Amryt and Aergerion has been concluded. For Gowling WLG, the deal represents further indication of our extensive experience in the life sciences market."

As part of the agreement, Amryt will receive an exclusive license to promote and distribute the drug, paying Aegerion sales-related milestone payments and royalties on product sales in the territories. Amryt will also be responsible for ongoing regulatory and post-marketing obligations and commitments in support of the brand.

Assisting Patrick on the deal included Mathilda Davidson, Alice Stagg, James Barr and Bernardine Adkins.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.